BioCryst Pharmaceuticals announced that the Health Services Executive (HSE) in Ireland has recommended Orladeyo (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Ireland will have access to the first oral, once-daily therapy for the reduction of recurrent HAE attacks.

Charlie Gayer, Chief Commercial Officer of BioCryst, said: “The positive HSE recommendation of Orladeyo broadens access to modern prophylaxis, providing greater choice for prescribing physicians and potentially a better quality of life for HAE patients in Ireland.”

The HSE decision in Ireland follows the European Commission marketing authorization of Orladeyo in April 2021. To date, Orladeyo is licensed in 44 countries.

(Source: BioCryst)